gemcitabine has been researched along with oridonin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bu, HQ; Chen, H; Guo, HC; Li, HH; Lin, SZ; Luo, J; Wang, ZH; Zhang, JH | 1 |
| Bu, HQ; Huang, H; Jin, HM; Li, Y; Liu, DL; Zhao, JF | 1 |
2 other study(ies) available for gemcitabine and oridonin
| Article | Year |
|---|---|
Oridonin enhances antitumor activity of gemcitabine in pancreatic cancer through MAPK-p38 signaling pathway.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Diterpenes, Kaurane; Drug Resistance, Neoplasm; Drug Synergism; Female; Gemcitabine; Humans; MAP Kinase Signaling System; Mice; Mice, Inbred BALB C; Mice, Nude; p38 Mitogen-Activated Protein Kinases; Pancreatic Neoplasms; Random Allocation; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2012 |
Enhancement of the effects of gemcitabine against pancreatic cancer by oridonin via the mitochondrial caspase-dependent signaling pathway.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Caspase 9; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cytochromes c; Deoxycytidine; Diterpenes, Kaurane; Drug Synergism; G1 Phase Cell Cycle Checkpoints; Gemcitabine; Humans; Mitochondria; Pancreatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Signal Transduction | 2014 |